Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 6/20 | 0.54 |
| ▸ | CSF1R | P07333 | 5/20 | 0.54 |
| ▸ | LCK | P06239 | 6/20 | 0.53 |
| ▸ | KIT | P10721 | 4/20 | 0.53 |
| ▸ | ABL1 | P00519 | 3/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 6/20 | 0.53 |
| ▸ | TEK | Q02763 | 5/20 | 0.53 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.52 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.52 |
| ▸ | RAF1 | P04049 | 1/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1499307 | 0.91 | FGFR1 (0.48) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL1499154 | 0.90 | LCK (0.51) | CSF1RLCKKITABL1SRC | |
| SCHEMBL3054046 | 0.90 | PTGS1 (0.47) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL1499372 | 0.89 | LCK (0.54) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL1499230 | 0.87 | CSF1R (0.48) | CSF1RKITABL1KDRDDR1 | |
| SCHEMBL3054044 | 0.85 | GAA (0.50) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL13097210 | 0.85 | BRAF (0.59) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL3060803 | 0.81 | FGFR1 (0.42) | CSF1RKITKDRDDR1FGFR1 | |
| SCHEMBL1499144 | 0.81 | NTRK1 (0.51) | BRAFCSF1RLCKKITABL1 | |
| SCHEMBL13097211 | 0.80 | BRAF (0.54) | BRAFCSF1RLCKKITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481539-B2 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-09 | — | — | US | claimed |
| EP-2229389-B1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Pharma AG (DE) | 2011-09-14 | — | — | EP | claimed |
| JP-2011506365-A | — | — | 2011-03-03 | — | — | JP | claimed |
| US-20100261730-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | claimed |
| EP-2229389-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-22 | — | — | EP | claimed |
| WO-2009074260-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | claimed |
| EP-2070929-A1 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | claimed |
| US-8481539-B2 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8481539-B2 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8481539-B2 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-09 | — | — | US | disclosed |
| EP-2229389-B1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | Bayer Pharma AG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261730-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100261730-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2070929-A1 | Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261730-A1 | ALKYNYLARYL COMPOUNDS AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME | ALK, ALKBH3, EDNRB | BRAF 719/4885CSF1R 1967/4885LCK 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.